Metraipolis › archive › dc_4dffe1733ff7

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS) — Europe PMC PMID:39861175

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/39861175
DOI
10.3390/ph18010114
License (as archived)
solo-consultazione
Archived
2026-10-08T06:35:41.103Z
SHA-256 of the archived text
22804721b44a5707bb557c64d9769d99fc8f0067b4ea4dfcd9a5e423f4a1dfc3
Stable URL of this page
https://metraipolis.com/documento/dc_4dffe1733ff7

How to cite

Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS) — Europe PMC PMID:39861175 — Europe PMC (en), https://europepmc.org/article/MED/39861175 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4dffe1733ff7 (Metraipolis archive dc_4dffe1733ff7, sha256 22804721b44a5707bb557c64d9769d99fc8f0067b4ea4dfcd9a5e423f4a1dfc3)
BibTeX
@misc{dc4dffe1733ff7,
  title = {Post-Marketing Pharmacovigilance of Canakinumab from the FDA Adverse Event Reporting System (FAERS) — Europe PMC PMID:39861175},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/39861175},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4dffe1733ff7; sha256 22804721b44a5707bb557c64d9769d99fc8f0067b4ea4dfcd9a5e423f4a1dfc3},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/39861175. Agents can read the archived copy with the MCP tool read_document.